Chitotriosidase Role in the Monitoring and Follow-up of Treatment in Gaucher Disease: A Review
Haidar A Abdulamir1*, Rasha K. J. Ali2, Ahmed Hameed Al Saeedi1
1College of Pharmacy, University of Hilla, Babylon 51001, Iraq.
2Department of Pharmacy, Al-Warka University College, Basra, Iraq.
*Corresponding Author E-mail: haider.adnan@hilla-unc.edu.iq
ABSTRACT:
Gaucher disease (GD) is an inherited autosomal recessive disorder and the most common lysosomal storage disease, caused by a deficiency of the enzyme glucocerebrosidase (acid β-glucosidase). The enzymatic defect leads to progressive accumulation of its substrate, glucocerebroside, within the lysosomes of macrophages of the mononuclear phagocyte system, giving rise to lipid-laden "Gaucher cells" that infiltrate the spleen, liver, bone marrow, and less frequently the lungs, kidneys and central nervous system1,2. The disease shows a marked ethnic predilection, being particularly prevalent among Ashkenazi Jews3.
Since the introduction of enzyme replacement therapy (ERT) with recombinant glucocerebrosidase, GD became the first lysosomal storage disease to be successfully managed pharmacologically, with marked improvement of hepatosplenomegaly and cytopenias within the first months of treatment4,5. Because the clinical response to ERT is gradual and variable among organs, objective, reproducible and sensitive laboratory biomarkers are essential for diagnosis, prognosis, and, most importantly, for the follow-up of the therapeutic response. Several surrogate markers of macrophage burden have been proposed, including tartrate-resistant acid phosphatase, angiotensin-converting enzyme, ferritin, and the chemokine CCL18/PARC6, an approach that mirrors the use of other single, sensitive circulating biomarkers to track disease activity in different clinical settings, such as ferritin in monitoring oxidative and inflammatory stress in diabetic patients with acute myocardial infarction7.
Among all proposed biomarkers, plasma chitotriosidase (ChT) has emerged as the most powerful and most widely validated for both the diagnosis and, in particular, the monitoring of the response to ERT in GD8-12. This review summarizes the biology of ChT, the pathophysiological basis of its elevation in GD, and the current evidence supporting its role in the monitoring and follow-up of enzyme replacement therapy, in comparison with other available biomarkers.
BIOLOGY AND ORIGIN OF CHITOTRIOSIDASE:
Chitotriosidase (ChT; EC 3.2.1.14) is a member of the glycoside hydrolase 18 (chitinase) family, encoded by the CHIT1 gene on chromosome 1q31-32. It is secreted almost exclusively by activated tissue macrophages and neutrophils, and, unlike most lysosomal hydrolases, is dramatically and specifically elevated in the plasma of patients with GD, reflecting the burden of lipid-laden Gaucher cells8,9. In the research laboratory, plasma ChT activity is most commonly determined by a fluorometric assay in which plasma is incubated with the synthetic substrate 4-methylumbelliferyl-β-D-N,N′,N″-triacetylchitotrioside, and the amount of liberated 4-methylumbelliferone is measured fluorometrically, a method first described by Guo et al13 and still widely used in clinical and research laboratories today.
CHITOTRIOSIDASE ELEVATION IN GD: PATHOPHYSIOLOGICAL BASIS:
The striking elevation of ChT activity in GD was first described by Hollak et al10, who reported plasma levels several hundred-fold higher than those of healthy controls and proposed ChT as a novel biochemical hallmark of the disease. Subsequent work established that ChT elevation reflects the degree of activation and differentiation of tissue macrophages in response to glucocerebroside accumulation, rather than the absolute number of Gaucher cells alone8, explaining both the very large baseline elevation observed at diagnosis and the comparatively rapid decline in activity that follows effective treatment. Levels of ChT decrease markedly during ERT and rise again upon its discontinuation, a pattern consistent with its origin as a secretory product of activated, rather than merely lipid-laden, macrophages9.
CHITOTRIOSIDASE AS A DIAGNOSTIC BIOMARKER:
Because ChT elevation in untreated GD is of such large magnitude, the marker performs exceptionally well diagnostically. In a case-control study of 67 Iraqi children with GD, sub-classified by duration of ERT and compared with 20 age- and sex-matched healthy controls, in the same cohort in which liver function tests were previously used to evaluate the hepatic response to treatment12,14, plasma ChT activity was markedly and significantly higher in untreated patients than in controls, and Receiver Operating Characteristic (ROC) curve analysis15,16 showed an area under the curve of 1.00, with 100% sensitivity and specificity, for distinguishing newly diagnosed patients from controls. This near-perfect diagnostic performance at presentation is consistent with findings reported across multiple international cohorts9,10 and supports the inclusion of ChT measurement in the initial diagnostic work-up of suspected GD, alongside enzymatic confirmation of glucocerebrosidase deficiency.
CHITOTRIOSIDASE IN THE MONITORING AND FOLLOW-UP OF ENZYME REPLACEMENT THERAPY:
The principal clinical value of ChT, however, lies in its use for monitoring and follow-up of the response to ERT. Kanneganti et al8 reported that ChT activity in Gaucher patients is elevated 10- to 1,000-fold in blood and demonstrates its sharpest decline during the first year of ERT, with the greatest treatment efficacy noted during the first six months, a pattern that closely mirrors the trajectory of visceral and hematological improvement seen with treatment4. In the Iraqi pediatric cohort referred to above12, ChT activity was highest in newly diagnosed, untreated patients and fell progressively and significantly with each successive stage of ERT, from three to six months, through six to twelve months, to more than one year of treatment17-20, with ROC curve analysis again yielding an area under the curve of 1.00, 100% sensitivity and 100% specificity for discriminating every pair of successive treatment-duration subgroups, outperforming every other biochemical parameter examined in that cohort.
Despite this rapid initial decline, ChT activity typically remains above the normal range even after prolonged treatment. Sumarac et al21 reported that ChT levels generally reach a plateau approximately two years after starting ERT and remain around ten times normal even after five years of continuous treatment, while discontinuation of therapy is followed by a renewed rise in enzyme synthesis and clinical recurrence of the disease. This persistence suggests that the decline in ChT activity with ERT reflects an alteration in the activation state of tissue macrophages rather than a complete elimination of the Gaucher cell burden, a mechanism further supported by data comparing substrate reduction therapy with ERT22. Consistent with the value of ChT as a follow-up tool, its serial measurement is recommended in the consensus guidelines for the evaluation and monitoring of children with type 1 GD11, and its decline has been shown to parallel the concurrent biochemical improvement observed across other organ systems, including the liver, in the same paediatric cohort12, reinforcing ChT as a composite indicator of overall disease burden rather than a marker limited to a single organ system23.
CHITOTRIOSIDASE COMPARED WITH OTHER BIOMARKERS OF DISEASE ACTIVITY:
Several other circulating biomarkers have been proposed for monitoring GD activity. The chemokine CCL18/PARC provides an alternative marker of macrophage activation with a response to ERT broadly similar in direction to ChT, and has been proposed as a complementary surrogate marker of therapeutic intervention, particularly useful in the subset of patients who are genetically deficient in ChT6. Ferritin, though non-specific, has similarly been used as a circulating marker reflecting macrophage and inflammatory activity in other chronic and acute disease states, illustrating the broader principle of using a single, sensitive biomarker to reduce reliance on invasive or purely clinical assessment during long-term follow-up7. Despite these alternatives, comparative studies and clinical experience consistently identify ChT as the single most sensitive and specific biomarker currently available for both the diagnosis and short-term monitoring of ERT response in GD9,11, a distinction that has contributed to persistent diagnostic delay in patients who are not tested with this marker at an early stage of their clinical presentation24.
LIMITATIONS OF CHITOTRIOSIDASE AS A BIOMARKER:
Two important limitations restrict the interpretation of ChT activity. First, substrate inhibition occurs at high, saturating concentrations of the conventional 4-methylumbelliferyl-triacetylchitotrioside substrate, meaning that measured activity does not always accurately reflect the true plasma ChT protein concentration9. Second, a common null polymorphism in the CHIT1 gene (c.1049_1072dup24) is present in the homozygous state in approximately 6% of individuals of European ancestry and completely abolishes enzymatic activity irrespective of underlying disease status; heterozygous carriers of this and other polymorphisms, such as p.G102S, show reduced activity that can lead to underestimation of true disease burden9. Genotyping for these polymorphisms is therefore recommended when ChT activity is unexpectedly low in a patient with otherwise typical clinical or biochemical features of GD, although this is generally considered more important for the interpretation of diagnostic values than for the monitoring of an individual patient's own serial measurements over time9.
FUTURE DIRECTIONS:
Further multi-centre, longitudinal studies extending well beyond the first year of ERT are needed to define more precisely the time-course over which ChT activity approaches a stable plateau, and to determine whether persistently elevated levels after long-term treatment carry independent prognostic significance for residual disease burden21,25-30. Combining ChT with complementary biomarkers, such as CCL18/PARC in genetically deficient patients, and with structural or hormonal indices of organ-specific involvement, is likely to provide the most complete assessment of treatment response, consistent with the broader move toward multi-biomarker panels in the long-term management of GD6,31,32.
CONCLUSION:
Plasma ChT activity is an excellent, highly sensitive and specific biomarker for the diagnosis of GD and remains the single most reliable and widely validated biochemical parameter currently available for the monitoring and follow-up of the response to enzyme replacement therapy in both children and adults with this disease. Despite recognized limitations related to substrate inhibition and CHIT1 gene polymorphisms, its serial measurement is recommended as a routine, minimally invasive component of the long-term follow-up protocol for patients with GD receiving enzyme replacement therapy.
REFERENCES:
1. Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol. 2005; 129(2): 178-188.
2. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet. 2008; 372(9645): 1263-1271.
3. Beutler E, Nguyen NJ, Henneberger MW, Smolec JM, McPherson RA, West C, et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet. 1993; 52(1): 85-88.
4. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002; 113(2): 112-119.
5. Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther. 2012; 6: 81-106.
6. Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 2004; 103(1): 33-39.
7. Mutaz Sabah A, Khdhair Abbas K, Shaymaa Mohammed Salih. The Relationship between Serum Level of Ferritin and Cardiac Troponin T (cTnT) in Children with Major Beta-Thalassemia. Research J. Pharm. and Tech. 2019; 12(4): 1713-1716.
8. Kanneganti M, Kamba A, Mizoguchi E. Role of chitotriosidase (chitinase 1) under normal and disease conditions. J Epithel Biol Pharmacol. 2012; 5: 1-9.
9. Irún P, Alfonso P, Aznarez S, Giraldo P, Pocovi M. Chitotriosidase variants in patients with Gaucher disease. Implications for diagnosis and therapeutic monitoring. Clin Biochem. 2013; 46(18): 1804-1807.
10. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease. J Clin Invest. 1994; 93(3): 1288-1292.
11. Awadh AI. The Role of Lipid Profile Assessment in Monitoring the effect of Imiglucerase in Children with Gaucher Disease. Res J Pharm Technol. 2023; 16(2): 573-0.
12. Abdulamir HA,Aldafaay AAA, Al-Shammari AH. The Role of Liver Function Tests in Monitoring the effect of Enzyme Replacement Therapy in Children with Gaucher Disease. Res J Pharm Technol. 2022; 15(8): 3490-6.
13. Guo Y, He W, Boer AM, Wevers RA, de Bruijn AM, Groener JE, et al. Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J Inherit Metab Dis. 1995; 18(6): 717-722.
14. Al-Kinani ZA, Ali SH. Serum Chitotriosidase level as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis among the Iraqi children. Iraqi Journal of Pharmaceutical Sciences. 2021; 30(1): 270-6.
15. Walia MS. Performance Analysis of Feature Extraction Techniques for Iris Pattern Recognition System. Research J. Engineering and Tech. 2017; 8(4): 431-435.
16. Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J Intern Med. 2013; 4(2): 627-635.
17. Czartoryska B, Tylki-Szymańska A, Górska D. Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT). Clin Biochem. 1998 Jul; 31(5): 417-20.
18. Ries M, Schaefer E, Lührs T, Mani L, Kuhn J, Vanier MT, Krummenauer F, Gal A, Beck M, Mengel E. Critical assessment of chitotriosidase analysis in the rational laboratory diagnosis of children with Gaucher disease and Niemann-Pick disease type A/B and C. J Inherit Metab Dis. 2006 Oct; 29(5): 647-52. doi: 10.1007/s10545-006-0363-3. Epub 2006 Jul 27. PMID: 16972172.
19. Bennett D, Cameli P, Lanzarone N, Carobene L, Bianchi N, Fui A, Rizzi L, Bergantini L, Cillis G, d'Alessandro M, Mazzei MA, Refini RM, Sestini P, Bargagli E, Rottoli P. Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis. Respir Res. 2020 Jan 6; 21(1): 6. doi: 10.1186/s12931-019-1263-z. Erratum in: Respir Res. 2020 Jan 29;21(1):34. doi: 10.1186/s12931-020-1303-8. PMID: 31906975; PMCID: PMC6945638.
20. Szymańska-Rożek P, Czartoryska B, Kleinotiene G, Lipiński P, Tylki-Szymańska A, Ługowska A. A 20-Year Longitudinal Study of Plasma Chitotriosidase Activity in Treated Gaucher Disease Type 1 and 3 Patients-A Qualitative and Quantitative Approach. Biomolecules. 2023 Feb 24; 13(3): 436. doi: 10.3390/ biom13030436. PMID: 36979371; PMCID: PMC10046580.
21. Linari S, Castaman G. Clinical manifestations and management of Gaucher disease. Clin Cases Miner Bone Metab. 2015; 12(2): 157-164.
22. Sumarac Z, Suvajdžić N, Ignjatović S, Majkić-Singh N, Janić D, Petakov M, et al. Biomarkers in Serbian patients with Gaucher disease. Clin Biochem. 2011; 44(12): 950-954.
23. Aldafaay AAA, Abdulamir HA, Abdulhussain HA, Badry AS, Abdulsada AK. The use of Urinary α-amylase level in a diagnosis of Chronic renal failure. Res J Pharm Technol. 2021; 14(3): 1597-1600.
24. Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017; 18(2): 441
25. Smid BE, Ferraz MJ, Verhoek M, Mirzaian M, Wisse P, Overkleeft HS, et al. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients. Orphanet J Rare Dis. 2016; 11: 28.
26. Aslan SK, Ozel Z. Compatibility of Charge Nurse Self-Assessments and Executive Nurse Evaluations: A 5-Year Multi-Center Study. International Journal of Advances in Nursing Management. 2024; 12(4): 151-7.
27. Raju CP, Babu GP, Sowjanya M, Ramayyappa M. Evaluation of Cancer Bio-markers through Hyphenated Analytical Techniques. Asian J Pharm. Anal. 2021; 11(3): 235-2.
28. Khatri M, Dhar S, Ven P, Singh A. Understanding the Pharmacological Mechanisms of Anticancer Resistance: A Multifaceted Challenge in Cancer Treatment. Asian J Pharm Res. 2024; 14(2): 183-7.
29. Mahajan S, Dave H, Bothe S, Mahpatra D, Sonawane S, Kshirsagar S, et al. Objective Monitoring of Cardiovascular Biomarkers using Artificial Intelligence (AI). Asian J Pharm Res. 2022; 12(3): 229-4.
30. Wale S, Lade S, Dalvi S, Katakdhond D, Desai A, Karnkoti A, et al. Smart Bandage: A Targeted Treatment and Wound Monitoring Device. Int J Technol. 2026; 16(1): 73-7.
31. Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007; 82(8): 697-701.
32. Chen M, Wang J. Gaucher disease: review of the literature. Arch Pathol Lab Med. 2008; 132(5): 851-853.
|
Received on 30.07.2026 Revised on 17.08.2026 Accepted on 02.09.2026 Published on 12.09.2026 Available online from September 19, 2026 Asian J. Research Chem.2026; 19(5):471-474. DOI: 10.52711/0974-4150.2026.00068 ©A and V Publications All Right Reserved
|
|
|
This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License. |
|